ClinicalTrials.gg
Not yet recruitingNCT07876518Updated Oct 15, 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity

A Phase 1 interventional study of Placebo and PF-08656795 in Overweight and/or Obesity, sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Obesity by Pfizer — 13 open to participants now, 19 under way, 12 of them phase 3. Obesity · Pfizer.

Planned enrollment
28th of 62
150 · median 127
Started
2026
with 18 others
Phase 1
30 of 64
3 open now
Primary completion
2028-11
later than 16 of 18 live
Registered
60th of 64
by date

Among the 64 studies in Obesity by Pfizer, this one is the 28th largest by planned enrollment of the 62 interventional ones that give a count, is one of 19 that started in 2026, is one of 30 in phase 1, reaches primary completion later than 16 of the 18 other live ones, and was the 60th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

13 of the 64 studies in Obesity by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Obesity by Pfizer, or all of them as a file.
02

Study summary

This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.

Doctors will check if each person meets the study conditions, including age, body weight, and general health. People with certain medical conditions will not be able to take part in the study.

The study is seeking participants who are:

  • adults, 18 to 70 years of age (inclusive)
  • have a body mass index (BMI) equal to, or more than 25 kilograms/meter square (kg/m2) up to 40 kg/m2.
  • limited mild, stable long-term medical conditions are allowed as assessed by the study doctor.

People who want to join the study will first go through a screening period of up to 4 weeks. The study will look at how the study medicine is tolerated, including whether participants have any reactions. It will assess how they feel after receiving multiple doses. It will also measure the amounts of study medicine in the blood and urine over time.

Participants will take part in this study for about 24 to 40 weeks including treatment and follow-up period after the final dose. Treatment duration may vary depending on their assigned group.

03

Conditions studied

  • Overweight and/or Obesity

Browse trials for

Keywords

  • overweight
  • obesity
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 150 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥25 to ≤40 kg/m2; with stable body weight for ≥3 months prior to screening.
  • Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension)

Exclusion criteria

Exclusion:

- Individuals with hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurological, or allergic disease, are not eligible to participate.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    PF-08656795

    Participants will receive PF-08656795 once a month or less frequently

    Drug: PF-08656795

  • Experimental
    Placebo

    Participants will receive placebo once a month or less frequently

    Drug: Placebo

Interventions

  • DrugPlacebo

    Given subcutaneously (under the skin).

  • DrugPF-08656795

    Given subcutaneously (under the skin).

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 12 weeks after last dose

Secondary outcomes

  1. Area Under the Curve from Time Zero to to time tau (AUCtau)

    Time frame: 0 (pre-dose), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 504, 672 hours post-dose

  2. Maximum Observed Concentration (Cmax)

    Time frame: 0 (pre-dose), 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 336, 504, 672 hours post-dose

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2028, 24 months later.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 24 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Nov 16, 2028
CompletionEst.
Nov 16, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07876518
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Nov 16, 2028 (estimated)
Completion
Nov 16, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion